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PROPHYLACTIC VACCINATIONS AND PATHOGENESIS OF MALARIA 
FROM PLASMODIUM FALCIPARUM 
ADDISON RAYNE SPARKS 
ABSTRACT 
 Malaria is a severe public health concern in certain regions, causing 445,000 
deaths and over 200 million cases in 2016 (Ashley et al., 2018). The vast majority of 
these cases and deaths are located in warm climates where the Anopheles mosquito is 
present, especially in sub-Saharan Africa and southeast Asia. Current efforts aim to 
prevent the disease through vaccination, which has proven to be challenging.  
 Plasmodium falciparum, the pathogen responsible for malaria, is transmitted 
between humans via the female vector Anopheles mosquito. This parasite has a complex 
life cycle that is not fully understood, making it difficult to treat the infection and even 
more difficult to inoculate a population through vaccination. P. falciparum is also capable 
of polymorphism, changing structure once a host antibody has identified a pathogenic 
antigen. For this reason, it is very technically challenging to develop a vaccine that is able 
to confer a high enough immune response through sufficient host antibody production.  
 This thesis will begin with a review on the prevalence and severity of malaria and 
an overview of the principles of immunology and vaccine development. We will then 
discuss the parasitic life cycle and how it results in the pathogenesis of the disease. 
Current antimalarial treatments and resistance to those treatments will be analyzed. This 
thesis will conclude with an in-depth analysis of the current prophylactic vaccines against 
P. falciparum, focusing on their mechanism, efficacy, and probability of success.  
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 Plasmodium falciparum is the most prevalent parasite responsible for the 
transmission of malaria tropica, an infectious disease typically found in tropical climates. 
Malaria, the leading cause of death from a vector-borne disease, is a severe international 
public health crisis and is responsible for 0.5 million deaths each year (Maier et al., 
2019). In 2019 there were an estimated 229 million cases worldwide, with only 2,000 
cases in the United States (CDC - Malaria - About Malaria, n.d.). This thesis will 
investigate the pathogenesis of malaria and the immunology of vaccination against the 
disease.  
Cases in the United States typically arise from travel to and immigration from 
countries where transmission is more common, mainly sub-Saharan Africa and South 
Asia (CDC - Malaria - About Malaria, n.d.). World regions of high transmission are 
demonstrated in Figure 1. These regions are warm, humid, tropical climates with large 
populations of the P. falciparum-transmitting mosquito, Anopheles. In populations where 
malaria transmission is present but stable with no spontaneous outbreaks, individuals can 




Figure 1: Map demonstrating worldwide malaria transmission. This figure represents 
the prevalence of malaria transmission in the world. Of note is the high transmission in 
sub-Saharan Africa and the pattern of transmission among tropical regions near the 
equator. Taken from (CDC - Malaria - About Malaria, n.d.). 
 
The genus Plasmodium encompasses many parasitic species, such as P. 
falciparum and P. vivax, that infect mammals, birds, and reptiles (CDC - Malaria - About 
Malaria, n.d.). Infections from these different species present similarly in clinic, but 
symptomatic malaria from P. falciparum is by far the most deadly, and is responsible for 
99.7% of malaria cases in Africa (Malaria, n.d.). P. falciparum is the most prevalent 
malaria-causing parasite in all world regions except for the Americas, where P. vivax is 
responsible for 75% of malaria cases (Malaria, n.d.). This thesis will focus on the 
transmission and progression of P. falciparum in human hosts.   
 The P. falciparum parasite is transmitted to humans from the female mosquito of 
the genus Anopheles (CDC - Malaria - About Malaria, n.d.). Female mosquitoes feed on 
blood to supplement egg production, and humans, by their number and size, are a great 
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source of fuel. The proboscis (shown in Figure 2) is a hollow, tubular mouthpiece that is 
used by the mosquito to suck blood from their food source. It is hypothesized that this 
proboscis has thermosensitive function and is used to accurately find blood vessels 
beneath the skin of Anopheles victims (Maekawa et al., 2011).  It is through this 
proboscis that the P. falciparum parasite is transmitted between the Anopheles mosquito 
and the human host. 
 
Figure 2: Diagram of an adult female Anopheles mosquito. This diagram shows the 
external anatomy of an adult female mosquito of the genus Anopheles, the genus 
responsible for malaria transmission. Feature of interest is the proboscis, which is used 




Like most other infectious diseases, the most effective method of protection 
against malaria is prevention. This disease is complicated, however, in that it is difficult 
to vaccinate against P. falciparum. This thesis will continue with a brief description of 
vaccination theory, an analysis of the P. falciparum life cycle and pathogenesis of 
malaria, and a review of the literature on current vaccination attempts against the disease.  
Immunology and vaccinology 
Vaccinations are effective measures to lower the prevalence of a disease in a 
targeted population. Herd immunity – when 75-95% of the population is vaccinated 
against a pathogen – is a marker of success in disease prevention. (Vetter et al., 2018). 
The healthy individuals that make up a majority of the population are vaccinated, 
reducing or halting disease transmission and protecting immunocompromised individuals 
that are unable to receive the vaccine.  
Vaccination  primes the body’s immune system against a disease so that when 
that disease is next encountered, the symptoms and spread of the disease are greatly 
reduced or even nonexistent. This protects the individual being vaccinated and the 
individuals surrounding them, as transmission is lowered. The immune system is divided 
into two overarching categories: innate and adaptive. The innate system involves several 
cell types that recognize pathogens and trigger the immune response. This system is 
nonspecific, fast, and does not retain memory of pathogens. The adaptive immune system 
involves cell-mediated immunity and a unique antigen-antibody interaction. This system 
involves B and T cell responses that target specific molecules, killing infected cells and 
retaining an immunological memory of pathogens. The adaptive immune system is 
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specific and lags between pathogen exposure and immune response. The antigen is the 
foreign molecule being targeted, and the antibody is produced by the host’s adaptive 
immune system in response to an antigen. The distinction between these categories is 
visualized in Figure 3.  
 
Figure 3: Visualization of the innate and adaptive immune systems. This diagram 
shows the main components of the adaptive and innate immune systems. The innate 
immune system is nonspecific and acts quickly; this system also encompasses physical 
barriers to pathogen entry. Retrieved from (National Center for Chronic Disease 




Physical barriers (Figure 3) are also present and critical for prevention of 
pathogen entry, but they do not act as quickly as the innate components. These properties 
include tight junctions between epithelial cells of the skin, mucus and mucosal 
membranes lining body orifices, and anatomical barriers that compartmentalize different 
regions of the body (Aristizábal & González, 2013). The skin and mucosal membranes 
are not only physical barriers but also contain cells that release antimicrobial peptides and 
other mediators that break down foreign material (Aristizábal & González, 2013).  
The innate immune system is nonspecific and involves the first line of defense 
against pathogens. Cells of this system work quickly, in as little as minutes. Phagocytic 
cells of the innate immune system, known as monocytes and macrophages, are present 
throughout the body and patrol for invading pathogens. These cells ingest and often 
digest foreign particles by extending their cell membrane and engulfing the unfamiliar 
pathogen (Aristizábal & González, 2013). The innate immune system also involves cells 
that release cytokines, inflammatory mediators, and antimicrobial granules that work to 
destroy the pathogen. The activation of these agents triggers a signaling cascade that 
stimulates the adaptive immune system to begin the process of acquired immunity. The 
histological appearance of the cells of the innate and adaptive immune systems are shown 





Figure 4: Histological preparation of immune cells in blood. Shown above are the 
appearances under hematoxylin and eosin staining of immune cells found in the blood. 
The lymphocytes belong to the adaptive immune system, all others are categorized under 
the innate immune system. Taken without alteration from (Megías et al., 2019).  
 
Monocytes (as they are referred to when in circulation) differentiate into 
macrophages (when in tissue) and are the primary phagocytic cells of the innate immune 
system and are visualized in Figure 4. These cells are significant in that they can present 
antigens to the adaptive immune system and activate lymphocytes (Aristizábal & 
González, 2013). After activation, they stimulate and release cytokine secretion, further 
modulate the immune response, and participate in tissue reorganization after infection.  
Dendritic cells are another member of the innate immune system that mainly 
reside in the skin and mucosa and function to present antigens to T-cells of the adaptive 
immune system. These cells are also referred to as antigen-presenting cells (APCs). 
Dendritic cells take up antigens through various mechanisms and present antigens on 
their surface via major histocompatibility complex (MHC) type II at lymph nodes, which 
is a concentrated area of adaptive immunity lymphocytes (Aristizábal & González, 2013). 
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These cells also regulate the adaptive T-cell response and regulate the activity of other 
innate immunity components.  
A group of cells named granulocytes appear in the early stages of innate 
immunity and work to phagocytize and destroy pathogens through the release of 
antimicrobial peptides, enzymes, and oxidation (Aristizábal & González, 2013). 
Eosinophils, neutrophils, basophils, and mast cells are all granulocytic cells responsible 
for these processes. Neutrophils (Figure 4) are very abundant and are the first cells 
recruited to an inflammatory site after the inflammatory process is stimulated (Aristizábal 
& González, 2013). These cells tag pathogens for later phagocytosis by antibodies and 
release lytic enzymes to destroy the pathogen.  
Eosinophils (Figure 4) degranulate and release antimicrobial enzymes and 
proteins that work to destroy pathogens, mainly parasites. As malaria is caused by the 
parasite P. falciparum, eosinophils and their anti-parasitic properties are of great 
importance to the study of the host response to malaria. Eosinophils also release 
histamine and inflammatory factors that are involved in the allergic response.  
Basophils (Figure 4) are not very prevalent in blood, and their function is poorly 
understood. Mast cells are located in connective tissue and release proinflammatory 
mediators, antimicrobial peptides, and proteases (Aristizábal & González, 2013). Neither 
basophils nor mast cells have phagocytic activity.  
The innate immune system is the first defense a pathogen faces when entering the 
body. Once a pathogen has been detected, the inflammatory response begins and the 
adaptive immune system is recruited through cytokines and other mediators. Adaptive 
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immunity is a vast and complex system, but this thesis will focus on the fundamentals as 
they relate to vaccine development. The main cells of the adaptive immune system are 
lymphocytes, which are divided into T cells and B cells. Lymphocytes are shown in 
Figure 4; T and B cells are indistinguishable in classic hematoxylin and eosin staining. 
Some T cells participate in cell-mediated immunity by directly acting against foreign 
pathogens to destroy them and others release cytokines to activate other components of 
the immune system and promote antibody production. B cells act within humoral 
immunity to produce antibodies, which recognize pathogens upon reinfection. Inducing 
the production of antibodies against a pathogen is the premise of vaccine administration 
and is especially important in malaria prevention.  
Vaccines can be prepared in many different forms. The most common type 
packages the pathogen as a live attenuated pathogen, meaning it is in a weakened form. 
Some are non-live vaccines that contain only a subunit of the pathogen, enough to be 
recognized by immune cells but not enough to be damaging to a patient. The vaccines 
against SARS-CoV-2 contain either mRNA or DNA that code for the spike protein of the 
virus (Pollard & Bijker, 2021). This non-live vaccine allows the immune system to 
recognize the virus spike protein and produce antibodies to combat future infection, but 
the rest of the virus is not present to harm the patient. Most non-live vaccines are also 
administered with an adjuvant that enhances their ability to induce an immune response 




Table 1: Types of vaccines in use and in development. This table outlines the types of 
vaccines currently in use and in development. Current vaccination efforts against P. 
falciparum are exploring several of these options. Taken from (Pollard & Bijker, 2021). 
 
 Once a vaccine is prepared from the above methods, it is thoroughly vetted for 
safety and efficacy and then released for clinical use. The following pathway is 




Figure 5: Immune response to a vaccine. This figure shows how an immune response 
to a vaccine is created. Emphasis is placed on the MHC-II pathway and production of 
memory B cells and long-lived plasma cells. Taken from (Pollard & Bijker, 2021). 
 
The vaccine is injected and the antigen, the pathogen molecule capable of 
stimulating the immune response, binds to cellular receptors and is taken up by APCs, 
typically dendritic cells (Pollard & Bijker, 2021). The dendritic cells are activated by 
adjuvant binding to the pattern recognition receptors (PRRs) and the cells travel to the 
lymph nodes, a concentrated area of lymphocytes. Through cellular trafficking processes, 
the antigen is taken up by the dendritic cell and the antigen (or a fragment of it) is 
presented by MHC class II molecules. MHC class I molecules are responsible for 
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presenting peptides in the cytoplasm and can present normal “self” antigens or indicate a 
viral intracellular infection. At the lymph node, this MHC-II-presented antigen interacts 
with the T cell receptor (TCR) on CD4+ T cells, inducing B cell proliferation (Pollard & 
Bijker, 2021). T cells are critical for proper B cell development (Akkaya et al., 2020). B 
cells develop in the lymph node and mature into short-lived plasma cells and long-lived 
memory B cells. The plasma cells synthesize and produce a large number of antibodies 
against the antigen, to combat the “infection” quickly. This causes a rapid increase in 
serum antibody levels for the following two-week period (Pollard & Bijker, 2021). Long-
lived plasma cells are also created and travel to bone marrow where they continue to 
produce antibodies for years, even decades (Pollard & Bijker, 2021). Memory B cells 
have extreme significance in vaccinology, as these cells lie waiting in lymphoid tissues to 
recognize antigens in case of future infection. When a host is infected again, these 
memory B cells induce faster antibody production, allowing the immune system to 
combat the pathogen more quickly (Akkaya et al., 2020).  
Activated by the self-antigen MHC I pathway, CD8+ memory T cells are also able 
to proliferate rapidly when re-exposed to a pathogen. CD8+ effector T cells are either 
helper (TH) or cytotoxic (TC) cells. The helper cells aid in inducing macrophages, B cell 
production, and TC activation. The cytotoxic T cells kill the cells infected by the pathogen 
(Alberts et al., 2002). T cells have many functions as immune regulators, activators, and 
directly kill infected cells. It is also well known that they are required to induce B cell 
development in lymph nodes, and thus are required for antibody production (Pollard & 
Bijker, 2021).  
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Antibodies (also referred to as immunoglobulins) are structurally classed as IgG, 
IgM, IgA, IgD, and IgE. IgD, IgG, and IgE have a common structure shown in Figure 6. 
These antibodies are Y-shaped with two identical light chains on the outside region of the 
Y and two heavy chains that are identical to each other on the inside region (Antibody 
Structure, 2021). The Fc (fragment crystallizable) region is glycosylated to elicit specific 
immune responses (Jennewein & Alter, 2017). They are bound to each other through 
disulfide bonds, and the light chain has a smaller molecular weight than the heavy chain. 
The tips of the “Y” are the variable Fab regions (fragment antigen binding domain), a 
chain of 110 amino acids where antigens bind to the antibody (Antibody Structure, 2021). 
While B cells quickly differentiate into antibody-producing plasma cells, maturation 
requires that the Fab region mutate to achieve a higher affinity. This mutation can occur 
within 10-14 days, but can also require more time (Tijani et al., 2018). This variable 
region is composed of the distal portions of both the light and heavy chains. The 
bifurcation point of the structure is known as the hinge region and allows for flexible 





Figure 6: Structure of a monomer antibody. The monomer antibody is composed of 
two identical light chains on the outside region and two identical heavy chains on the 
inside region. These chains are held together through disulfide bonds. The variable Fab 
region is responsible for antigen binding. Taken from (Antibody Structure, 2021). 
 
The antigen-antibody interaction is fundamental to vaccine efficacy. When first 
infected with a pathogen, the host creates an arsenal of antibodies ready to recognize and 
destroy the antigen upon subsequent exposure. The ingenuity of vaccine development is 
to exploit that relationship and inoculate the population against a disease without needing 
to suffer the full symptomatic range of the disease. By exposing individuals to a small 
portion of the pathogen, their immune systems are able to mount a response that then lies 
waiting for exposure to the actual pathogen. This confers the advantage of having 
antibodies ready to recognize the invader and kill the infected cells quickly, saving the 
host from severe illness.  
Specific aims and objectives 
 A primary goal of this thesis is to investigate the life cycle of Plasmodium 
falciparum and how the parasite’s life stages correlate to symptomatic disease 
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presentation. Secondly, this thesis will review the current prophylactic vaccinations 
against malaria both in development and available to the public. This review will focus 
on the mechanism, efficacy, and probability of success of these vaccines. I will discuss 





PATHOGENESIS OF MALARIA 
 
 Malaria is classed as a vector-borne disease, the vector being the female 
Anopheles mosquito and the disease being caused by the parasite carried by the vector, 
Plasmodium falciparum. Infection with this parasite can result in a wide range of 
symptoms, from mild flu-like symptoms to anemia and death (Maier et al., 2019). P. 
falciparum replication requires hepatocytes, meaning that it is an obligate intracellular 
parasite. Replication within these cells of the liver is generally symptom-free, but 
symptoms are shown once the parasite enters in blood erythrocytes (Maier et al., 2019). 
Symptoms of malaria develop quickly as P. falciparum asexually replicates in 
erythrocytes, because a full replication cycle only takes 48 hours (Maier et al., 2019). As 
this stage causes symptoms and clinical presentation, this is the stage in which malaria is 
diagnosed. This portion of the thesis will continue with an explanation of the P. 
falciparum life cycle and a description of the symptoms and clinical presentation. Further 
sections will discuss prophylactic vaccinations against the parasite and the challenges in 
development.  
 
Life cycle of Plasmodium falciparum 
  The unicellular parasite P. falciparum has a complex life cycle, making it difficult 
to vaccinate against. A high number of developing parasites in blood allows for easy 
transmission, and the parasite quickly mutates to evade the host immune response. This 
life cycle is diagrammed in Figure 7. To begin, the female Anopheles mosquito injects its 
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proboscis into the dermis of a human target, inadvertently transferring the pathogen into 
human circulation in the sporozoite (spore-like) form. (CDC - Malaria - About Malaria, 
n.d.). From circulation, these sporozoites infect hepatocytes in the liver. They enter the 
liver by exiting sinusoids through Kupffer or endothelial cells, gaining entry to the 
hepatocyte. (Cowman et al., 2016). Entry into the liver requires the binding of the coating 
circumsporozoite protein (CSP) to the heparin sulfate proteoglycans (HSPGs) on 
hepatocytes. In these liver cells, sporozoites mature into schizonts, which are cells 
capable of producing daughter cells. (Maier et al., 2019). These schizonts reproduce 
asexually and lyse to release merozoites into the blood. Plasmodium vivax and 
plasmodium ovale, other causes of malaria, can lie dormant in the liver as hypnozoites 
and cause malaria years after infection (CDC - Malaria - About Malaria, n.d.). The agent 
studied in this thesis, Plasmodium falciparum, does not typically lie dormant and instead 





Figure 7: Life cycle of Plasmodium falciparum. The plasmodium falciparum 
sporozoites are transferred from Anopheles mosquito to a human host, where they mature 
in the liver, lyse hepatocytes, and are released into blood. The schizonts reproduce 
asexually in the blood and produce malarial symptoms. Some parasites develop into 
gametocytes, which are taken up by mosquito blood feeding and sexually reproduce in 
the mosquito. These oocysts develop into schizonts, which are poised to infect the next 
human host. Taken from (Maier et al., 2019).  
 
The liver stage of P. falciparum replication is referred to as exo-erythrocytic 
schizogony, and the stage of replication in the blood is referred to as erythrocytic 
schizogony (CDC - Malaria - About Malaria, n.d.). Schizogony is the asexual 
reproduction of a parasite through multiple fission, where many daughter cells are formed 
from a single parent cell. The nucleus of the parent cell divides multiple times through 
amitosis, and the cytoplasm separates to create daughter cells. One hepatocyte can release 
as many as 40,000 merozoites into the bloodstream (Cowman et al., 2016).  
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Merozoites exit the liver and reenter blood circulation, where they enter 
erythrocytes through receptor binding and endocytosis. Upon entering the red blood cell, 
the parasite is referred to as a trophozoite in the ring stage (Maier et al., 2019). These ring 
stage merozoites develop into mature merozoites, which further develop into schizonts. 
These erythrocytic schizonts, like the hepatocytic schizonts, rupture and release 
merozoites into the bloodstream. Merozoites released into blood enter the surrounding 
erythrocytes, and the replication cycle repeats and spreads rapidly. These blood-stage 
parasites are extremely significant as they are responsible for the clinical symptoms of 
malaria (CDC - Malaria - About Malaria, n.d.). Schizonts and ring stage trophozoites are 
shown below in Figure 8.  
 
           
Figure 8: Schizonts and ring stage trophozoites of P. falciparum. Shown on the left 
are purple-stained schizonts within an erythrocyte, ready for release. On the right are ring 
stage trophozoites, a less mature form of schizonts. The rounded pink structures are 





After invading a terminally differentiated erythrocyte, the erythrocyte is converted 
into a cell that can host and hide the parasite as it grows (Cowman et al., 2016). P. 
falciparum accomplishes this by exporting pathogenic proteins to various locations in the 
erythrocyte. The most studied protein of this phenomenon is the P. falciparum 
erythrocyte membrane protein 1 (PfEMP1) (Cowman et al., 2016). When this protein is 
displayed on the surface of erythrocytes, it is vulnerable to detection by human host 
antibodies. When the PfEMP1 protein is recognized, the parasite switches to expression 
of a different isoform, evading the host immune system (Cowman et al., 2016). From 
switching expression of the var gene responsible for this protein, approximately 60 
isoforms of PfEMP1 are possible (Hviid & Jensen, 2015).  This is a significant challenge 
in vaccine development – we can produce antibodies against the parasite, but once those 
antibodies begin working, the parasite changes its expression just enough that the old 
antibodies no longer recognize it. This mechanism of diversification evades host 
immunity and nullifies classical vaccine development (Cowman et al., 2016). 
The replication cycle in blood is asexual, except for one alternate route. Some 
ring stage trophozoites can differentiate into gametocytes rather than progressing into 
mature trophozoites. These gametocytes are capable of sexual reproduction in 
erythrocytes (Maier et al., 2019). The gametocytes will travel to the bone marrow to 
mature, and re-release within 15 days as mature male and female gametes (Cowman et 
al., 2016). When a second Anopheles mosquito feeds on the human host, the gametocytes 
are inadvertently transferred from the human bloodstream into the probiscis of the 
mosquito. The parasite resides in the epithelium of the mosquito’s midgut and replicates 
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through the sporogonic cycle (CDC - Malaria - About Malaria, n.d.). In the midgut, 
microgametes enter into macrogametes and create a zygote (Cowman et al., 2016). Over 
24 hours, these zygotes elongate and mature into an ookinete, which penetrates the 
basement membrane of the midgut epithelium. In the midgut wall, the ookinetes develop 
into oocysts, which further develop and lyse to release sporozoites (CDC - Malaria - 
About Malaria, n.d.). These sporozoites enter the hemocoel, the primary body of 
circulatory fluid in invertebrates, like mosquitoes (Cowman et al., 2016). The sporozoites 
travel through the fluid to the mosquito’s salivary glands, where they are poised to be 
deposited into a new target during the mosquito’s next blood feeding.  
 
Pathogenesis and clinical presentation 
 Infection of P. falciparum in a naïve (never-infected) individual almost always 
produces illness, unlike P. vivax and P. ovale which can lie dormant for long periods of 
time (Cowman et al., 2016). A typical incubation period before symptoms begin is 
around 7 days for malaria from P. falciparum (CDC - Malaria - About Malaria, n.d.). 
Disease severity positively correlates with the extent and severity of P. falciparum 
infection (Luzolo & Ngoyi, 2019). Disease pathogenesis stems from the exponential 
parasite growth, effects on the cardiovascular system, and activation of host immune and 
inflammatory cascades (Milner, 2018). The parasite replicates so rapidly that there is a 
10-fold increase in host parasite concentration every 48 hours (Cowman et al., 2016). The 
exponential growth of the parasite triggers the immune system response and an acute 
inflammatory response, which causes severe symptoms for the human host. As P. 
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falciparum develops and replicates in erythrocytes, it releases waste factors like 
hemozoin pigment and glucose phosphate isomerase (GPI) (CDC - Malaria - About 
Malaria, n.d.). These toxic substances are released into the bloodstream and stimulate 
immune cells, especially macrophages, to produce cytokines and other factors. These 
cytokines and immune factors induce the development of fever, rigors, (feeling of cold 
and shivering when having a fever), and many other symptoms of infection. High 
concentrations of inflammatory factors, specifically tumor necrosis factor (TNF), are 
strongly correlated with increased severity and death (Kwiatkowski et al., 1990). These 
heightened immune and inflammatory responses contribute to both local and systemic 
effects of malaria.  
 Initial symptoms of malaria infection, when they occur, are nonspecific and 
include headache, nausea, muscle aches, fatigue, sweating, feeling cold and shivering, 
and a fever (Cowman et al., 2016). Patients can also experience a sensation of cold 
followed by a sensation of hot, accompanied by vomiting and seizures in young children 
(CDC - Malaria - About Malaria, n.d.). At this stage, the infection can be controlled with 
administration of antimalarial drugs and is generally curative. Completion of a treatment 
regimen will eliminate P. falciparum infection, but not P. vivax or P. ovale. While a 
regimen will completely eradicate the infection from the host, it takes a significant toll on 
the energy of the host (Cowman et al., 2016). Pregnant women with malaria experience 
anemia and birth infants with low birth weight. (Cowman et al., 2016). Fighting a P. 
falciparum infection and developing a fetus takes a great amount of energy, and the 
placenta is a new site for parasite sequestration (Cowman et al., 2016). In those treated 
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for malaria, reinfection can occur due to an incomplete treatment regimen or the 
development of resistance to a drug.  
 In patients where treatment is not completed or not initiated, the initial infection is 
not controlled and can progress to severe malaria and eventually death. Severe malaria, 
the gravity of which varies depending on patient age and immune health, is marked by 
severe anemia, hyperparasitemia, cerebral malaria, and acute respiratory distress 
syndrome (ARDS) (Cowman et al., 2016). Anemia results from the heightened lysis of 
erythrocytes during P. falciparum blood stage replication. Cerebral malaria is the 
presence of coma under P. falciparum infection. This is likely caused by extensive 
storage of mature parasites in the microvasculature of the cerebrum (Wassmer et al., 
2015). Respiratory effects are from the increased capillary permeability and endothelial 
damage from heightened immune modulators, which leads to alveolar damage and 
impaired oxygen exchange (W. R. J. Taylor et al., 2012). Respiratory damage also occurs 
due to increased sequestration of infected erythrocytes through the same mechanism as 
cerebral malaria, which is discussed later (David et al., 1983). Severe malaria also affects 
the liver, causing jaundice, and the kidneys, inducing acute renal failure. Other symptoms 
include pulmonary edema, hypotension, and hypoglycemia. Anemia is severe and 
hemoglobinuria is present due to increased erythrocyte hemolysis (CDC - Malaria - 
About Malaria, n.d.). As a result of liver failure, gluconeogenesis is inhibited, resulting in 
hypoglycemia that is exacerbated by the increased need for glucose to fight infection 
(Thien et al., 2006). Hypoglycemia due to an increased demand for glucose is a frequent 
complication, especially in children (Thien et al., 2006). There is an especially high risk 
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of hypoglycemia in infected pregnant women due to the increased energy need (Cowman 
et al., 2016). Risk of death is greatly increased by organ failure and metabolic acidosis 
from respiratory failure (Wassmer et al., 2015). Severe malaria in children typically only 
presents with anemia and cerebral malaria, not organ dysfunction.  
 The most concerning clinical presentation of P. falciparum malaria is cerebral 
malaria. The parasite-infested erythrocytes are sequestered into the vascular endothelium, 
engorging the cerebral capillaries and post-capillary venules (Luzolo & Ngoyi, 2019). It 
is unclear exactly which pathogenic proteins are responsible for binding to the 
endothelium. It is hypothesized that endothelial intercellular adhesion molecule 1 
(ICAM-1) or endothelial protein C receptor (EPCR) could be involved (Wassmer et al., 
2015). This process triggers an inflammatory response, which then results in vascular 
leakage as a result of cytokine mediators. This blockage of capillary flow and increased 
vascular leakiness hinders oxygen distribution to brain tissue, causing hypoxia. Hypoxia 
of the brain causes immediate tissue damage and the edema compresses the respiratory 
center, causing coma and death very quickly (T. E. Taylor & Molyneux, 2015). This 
microvascular disruption also affects the blood-brain barrier, making neuronal tissue 
more susceptible to inflammation and damage from elements in the blood (Jensen et al., 





Figure 9: Sequestration of P. falciparum-infected erythrocytes in cerebral 
vasculature. Shown are the two mechanisms of P. falciparum-infected erythrocyte 
sequestration into cerebral microvasculature. This causes cerebral malaria, which leads to 
hypoxia of the brain tissue, neurological deficits, coma, and death. Taken from (Wassmer 





The primary symptoms of cerebral malaria are neck stiffness, muscle pain, 
headache, and coma (Luzolo & Ngoyi, 2019). Seizures, tooth grinding, and retinopathy 
are also noted in malaria infection. The presence of retinopathy is used to determine 
whether a coma is caused by malaria or another disease. This is especially important in 
resource-poor areas that do not have great access to brain imaging. Malarial retinopathy 
is characterized by retinal whitening, changes in the vasculature, hemorrhaging through 
the retina into the vitreous humor, and papilledema, a swelling of the optic nerve (Luzolo 
& Ngoyi, 2019).  
Survivors of cerebral malaria are often left with significant permanent 
neurological dysfunction. The hypoxia induced by cerebral malaria results in long-term 
brain damage. This dysfunction includes cognitive and behavioral abnormalities, motor 
difficulty, and epilepsy (Luzolo & Ngoyi, 2019). Behavioral and mental health problems 
are common in children, but also observed in adults (Idro et al., 2016). In adults post-
infection, it is possible to experience one-sided paralysis (hemiplegia), cerebral palsy, 
partial blindness, deafness, ataxia, and impaired learning ability (Luzolo & Ngoyi, 2019).  
Diagnosis of malaria is difficult, as the symptoms can be attributed to influenza or 
other common infections, especially in areas where malaria is not prevalent. In clinic, 
patients can present with fever, sweating, weakness, jaundice, enlargement of the liver 
and kidney, and increased respiratory rate leading to respiratory difficulty (CDC - 
Malaria - About Malaria, n.d.). Definitive diagnosis relies on microscopy and 
visualization of the parasites in a blood sample. Other diagnostic findings include anemia 
and decreased blood platelets (thrombocytopenia), elevated bilirubin, hypoglycemia, and 
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elevated aminotransferases from liver dysfunction (CDC - Malaria - About Malaria, 
n.d.). High levels of eosinophils (eosinophilia) may also be present, but this finding alone 
is not sufficient for diagnosis (Kurtzhals et al., 1998).  
 
Antimalarials and resistance 
 The first-line drugs for treatment and prevention of malaria are known as 
antimalarials. Treatment is ideally based around the knowledge of the Plasmodium 
species responsible and the density of the parasite in the host. Knowledge of the region 
where infection occurred, and the parasite species is especially important in estimating 
the likelihood of drug resistance. P. falciparum is especially prone to developing 
resistance to antimalarial drugs. The Centers for Disease Control and Prevention (CDC) 




Figure 10: CDC treatment flowchart for malaria. This chart shows the diagnostic and 
treatment procedures recommended by the CDC for the identification and treatment of 
malaria. Note dependence on the type of Plasmodium and where the infection was 
transmitted. Taken from (CDC - Malaria - About Malaria, n.d.). 
 
Chloroquine, the first antimalarial drug, works by inhibiting the parasite 
detoxification of hematin, a toxic byproduct released as the parasite consumes host 
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hemoglobin (Wellems & Plowe, 2001). Inhibiting this detoxification poisons the parasite, 
killing them in the blood stage and hindering infection. Alkaloid quinine is one of the 
oldest known treatments of malaria, and was initially isolated in 1820 from the Cinchona 
trees in South America (Madhav & Hoda, 2021). The structure of chloroquine and other 
quinine-based drugs are shown in Figure 11. These structures share a 4-aminoquinoline 
group, and other antimalarials share a 9-aminoquinoline group (Madhav & Hoda, 2021). 
Unfortunately, chloroquine resistance is quite widespread, especially in P. falciparum. 
The development of this resistance required multiple mutations in the gene pfcrt, 
resulting in reduced accumulation of the drug in the parasite’s digestive vacuole 
(Wellems & Plowe, 2001). Therefore, the drug does not significantly inhibit 
detoxification of hematin, and the parasite can continue digesting hemoglobin as normal. 
 
 
Figure 11: Structure of chloroquine and other quinine antimalarials. Shown are the 
organic structures of several quinine-based antimalarials, including chloroquine. 
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Common to all structures is the 4-aminoquinoline group, highlighted in orange. Taken 
from (Madhav & Hoda, 2021). 
 
 
Since chloroquine resistance is so widespread, the current first-line drug for 
treatment of uncomplicated malaria is artemisinin-based combination therapies (ACTs) 
(Cowman et al., 2016). Combination therapies provide the most effective route, as it is 
less likely that the pathogen will develop resistance to multiple drugs at once. If the 
pathogen develops resistance to one drug, it is likely that another component of the 
combination therapy will still be lethal to the parasite. It is not understood how 
artemisinin is lethal to the parasite, but it is known that it induces hemoglobin 
degradation through heme-mediated opening of the endoperoxide ring (Cowman et al., 
2016). This open heme releases oxygen, causing increased oxidative stress and death in 
the parasite. Recent studies have shown a small amount of artemisinin resistance through 
mutations in the gene that encodes a K13 propeller protein (Cowman et al., 2016). It is 
still uncertain what exact role this protein has in developing artemisinin resistance. There 
is evidence that a target of artemisinin is the P. falciparum phosphatidylinosilot-3-kinase 
(PfPI3K), and mutation in this gene can also confer resistance (Mbengue et al., 2015). 
Other studies have shown that artemisinin resistance is achieved through a slower 
development phase, nullifying the oxidative damage caused by artemisinin (Mok et al., 
2015). These resistant strains of P. falciparum are better able to correct oxidative damage 
through a more effective cell stress response.  
Antimalarial amino alcohols are a possible new medication class. These drugs 
contain an aromatic structure linked to an amino alcohol by a small chain of carbon 
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atoms and exhibit anti-plasmodial activity (Madhav & Hoda, 2021). Antifolate drugs 
have also shown promise in combatting P. falciparum infection and are used as a 
component of ACT. However, resistance has been shown to develop against these drugs, 
so they necessitate use in combination (Madhav & Hoda, 2021). Recent research has tried 
using antibiotics to combat malaria, but unfortunately they have not been very effective 
(Madhav & Hoda, 2021). Aside from efficacy, administration of antibiotics is challenging 
as they must be given in large doses and act much slower than the current lineup of 
antimalarials.  
A new class of antimalarials, called sesquiterpene lactone endoperoxide, shows 
promise and may overcome the rapid progression of malaria and development of 
chloroquine resistance (Madhav & Hoda, 2021). Endoperoxides are already used as 
antimalarials in artemisinin, the current first-line therapy. Artemisinin belongs to the first 
generation of endoperoxides, and research is currently underway for second generation 
endoperoxides (Madhav & Hoda, 2021). These drugs are not administered as 
monotherapies to deter the development of resistance. The structure of these compounds 





Figure 12: Structure of sesquiterpene lactone endoperoxide drugs. Arterolane and 
arteflene are second generation endoperoxide antimalarials. All other structures pictured 
are first generation. Note the common endoperoxide ring, with the common structure C-
O-O-C. Taken from (Madhav & Hoda, 2021).  
 
 
Treatment of severe malaria includes the use of current first-line medications as 
well as support for dysfunctional organs. For patients in severe respiratory distress, 
mechanical ventilation may be required. Patients suffering from seizures second to 
cerebral malaria are typically given anticonvulsants, such as phenobarbital and diazepam 
(Luzolo & Ngoyi, 2019). Fluids are used to alleviate hypoglycemia and dehydration and 
acetaminophen is administered for fever. The standard administration of fluids also tends 
to alleviate the metabolic acidosis, or at least make it manageable. Current research is 
focusing on the use of adjunctive therapies to target specific pathways, such as reducing 
oxidative stress and modulating the immune response. Unfortunately, sufficient evidence 
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for these therapies is not yet published, but researchers are hopeful that these therapies 
could provide new avenues of treatment (Luzolo & Ngoyi, 2019).  
While prevention is the preferred method of fighting malaria, we will discuss the 
difficulty in vaccine development. As we turn to compounds that stop the infection, the 
main concern is the development of resistance. Malaria is a serious public health concern 
and the development of resistance is racing against the research to find a suitable cure 
(Cowman et al., 2016). Current clinical trials are focusing on inhibiting vital processes 
and reproductive cycles of the parasite through direct targeting of a known component or 







VACCINATION AGAINST PLASMODIUM FALCIPARUM 
 
 
 It is widely accepted that vaccination is a required tool for completely controlling 
malaria and working toward global eradication (Cowman et al., 2016). Previous 
vaccination attempts have focused on targeting the pre-erythrocytic and erythrocytic 
stages in humans and the sexual stages in the mosquito. An overview of vaccines in 
clinical development as of 2018 is shown in Figure 13 below. 
 
Figure 13: Vaccinations against P. falciparum in development. This diagram shows 
the classes of vaccinations in development against P. falciparum as of 2018, the time of 
the source article publishing. This is intended to give a brief overview, a detailed 




Current emphasis on vaccine development subscribes to a phenomenon known as 
the bottleneck hypothesis. The bottleneck hypothesis focuses on the “numerical 
bottlenecks” of the parasitic life cycle, such as how many sporozoites are injected into the 
human host and transmission in the mosquito’s midgut (Cowman et al., 2016). The idea 
is that targeting these stages will increase vaccine efficacy, versus targeting the blood-
stage parasite that is present in very high numbers and has a knack for evading host 
immunity. An overview of the possible vaccine targets under this hypothesis are shown 
below in Figure 14. This thesis will culminate with a discussion of current vaccination 




Figure 14: Vaccine targets in the bottleneck hypothesis. Each numbered event is a 
possible vaccine target, according to the bottleneck hypothesis. High efficacy is 
important as a vaccination will be very stage specific and unable to combat multiple 





Sporozoite subunit vaccines 
 By far the most developed and researched vaccine against P. falciparum malaria 
is the RTS,S/AS01 vaccine, first developed in 1987 but deployed in 2019 (Laurens, 
2020). It is named for its composition – the “R” stands for the repeat region of the 
circumsporozoite protein (CSP), the “T” is for the part of the molecule that a T cell 
attaches to, and the “S” is for the hepatitis B surface antigen (HBsAg), an immune 
activator and carrier matrix (Draper et al., 2018). This vaccine targets the CSP that is the 
main protein in the sporozoite surface, triggering the production of anti-CSP antibodies. 
The vaccine targets the pathogen before the pathogen enters liver hepatocytes (Laurens, 
2020). In theory this vaccine should prevent blood-stage infection, but it is not 
completely protective and some sporozoites do leak through (Palacpac & Horii, 2020). 
The AS01 adjuvant system is relatively new and is composed of liposomes and 
formulation buffer (Laurens, 2020). The addition of this adjuvant improves vaccine 
efficacy by enhancing immune system activation. Clinical trials are underway to assess 
the effectiveness of this adjuvant system in specific cases, like severe malaria 
(Didierlaurent et al., 2017). The structure of CSP and the RTS,S antigen are shown below 





Figure 15: CSP and RTS,S structure. The top structure is the circumsporozoite protein 
(CSP) that encapsulates the sporozoite. This is the antigen that the RTS,S vaccine uses to 
generate an immune response. Taken from (Laurens, 2020).  
 
 
The RTS,S vaccine is intended to vaccinate children at 5 months of age, with 
subsequent administrations at 6 and 7 months and a booster dose 1-1.5 years after the 
third dose (Vandoolaeghe & Schuerman, 2016). When administered to children less than 
6 weeks old, the vaccine was not effective (McCall et al., 2020). This is the only vaccine 
that has shown efficacy against P. falciparum malaria, but it is only partially effective 
and the efficacy decreases over time (Draper et al., 2018). The high repeat structure 
presents more of the antigen to the immune cells, generating an enhanced immune 
response. Over the first year after a three-dose vaccination schedule, the incidence of 
malaria was reduced by 51% (RTS, 2015). After four years, however, efficacy drops to 
just 26%, which is far from a sustainable threshold. The most pressing issue is that high 
enough antibody levels cannot be sustained in the host (Draper et al., 2018). Future 
vaccines must take into account the constant decline in antibody concentrations. This can 
possibly be accounted for with improved adjuvants and administration of repeated 
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vaccines, although the latter is complicated in large scale distribution. Concerns have also 
been raised over the safety of vaccination. Some evidence has suggested that mortality 
rate is increased in female vaccine recipients (Guerra Mendoza et al., 2019). There is also 
evidence for an increased risk of meningitis after vaccine administration. The World 
Health Organization (WHO) is overseeing longitudinal cluster randomization trials in 
Ghana, Kenya, and Malawi, to test safety and efficacy, and results are expected in 2024 
(McCall et al., 2020). The RTS,S vaccine has not been studied as intensively in adult 
populations, but current studies have shown modest to insignificant vaccine efficacy 
(Moon et al., 2020). A study conducted in Thailand found that, when the RTS,S vaccine 
is combined with antimalarial medication, adult anti-CSP antibody production was 
induced in 90% of participants (von Seidlein et al., 2020). While efficacy is modest, the 
RTS,S/AS01 vaccine is currently the best option for malaria prevention and is the only 
one to complete phase III testing (Laurens, 2020).  Further vaccine development aims at 
lengthening the period of effectiveness without needing to administer booster doses every 
few years.  
A new area of vaccine development is structure-based vaccine design. This 
involves isolating an antibody from a human that was previously exposed to a pathogen 
through infection or vaccine (Kwong, 2017). This structure is then analyzed and used to 
develop antigens that can be used for large-scale vaccine development. Researchers use 
wild-type antibody generation as models to formulate antigens that can be used in further 
vaccines. One possible mechanism demonstrated through this technique is the generation 
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of antibodies against NANP, the repeat region of CSP (Oyen et al., 2017). This anti-
NANP antibody structure sets the stage for new antigens in further vaccine development.  
	
Vaccinations against the whole sporozoite 
Current studies of vaccines that target the entire sporozoite show promise. These 
studies aim to determine the efficacy of these vaccines in populations where malaria is 
very prevalent (Draper et al., 2018). These vaccines are typically live attenuated vaccines, 
weakened forms of the entire sporozoite that were described earlier in Table 1. Whole 
sporozoite vaccines can arrest the infection in both the liver and blood stages, but it is 
more beneficial to target the liver stage, as the malaria is not yet symptomatic. The first 
whole sporozoite vaccine studied is referred to as radiation-attenuated sporozoites (RAS), 
which targets infection at many points of liver infection (Draper et al., 2018). The 
response to these vaccines in trials recruited cytotoxic CD8+ T cells, which are very 
effective in eliminating parasite-infected hepatocytes (Doll & Harty, 2014). However, 
other trials do not show consistent levels of CD8+ activation (Moser et al., 2020).  
This vaccine is also referred to as the P. falciparum sporozoite vaccine (PfSPZ). 
The PfSPZ vaccine is administered intravenously and has shown overall promising 
results. Due to experimental design it is difficult to directly compare its efficacy, but the 
PfSPZ vaccine did lower the infection rates of adults in Mali compared to control, which 
showed efficacy of 52-71%, depending on the endpoint used (Sissoko et al., 2017).  
Another strategy of inoculating hosts against the whole sporozoite is 
administering P. falciparum sporozoites jointly with chloroquine. The sporozoites are 
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allowed to develop fully in the hepatocytes, but once the merozoites are released in the 
blood, they are killed through the chloroquine mechanism described earlier (Draper et al., 
2018). This method was shown to be protective of 100% of participants eight weeks after 
vaccination and still offered protection in 66% of participants two years later 
(Roestenberg et al., 2011). However, a more recent study showed that this method is not 
very effective when patients are infected with two different pathogenic strains (Walk et 
al., 2017). The exact mechanism of this ineffective attempt is still unclear. Despite this 
challenge, it is still promising that a vaccine has shown great effectiveness against a 
single Plasmodium falciparum strain. 
It was only in 2010 that whole sporozoite vaccine production became practical, as 
it is an extensive process (Duffy & Patrick Gorres, 2020). This process involves 
harvesting the sporozoite directly from mosquito salivary glands, which is a labor-
intensive process, and the whole sporozoites must also be purified and frozen. This 
vaccine must also be delivered directly into a vein to confer protection for the host. The 
efficacy of this vaccine is directly correlated to dosage, so large dosages or frequent small 
dosages must be administered to provide protection and have significant efficacy (Duffy 
& Patrick Gorres, 2020). Just like the RTS,S vaccine, duration of protection is a great 
concern. While the results of this vaccination method are promising, it is logistically 




Vaccinations against exo-erythrocytic schizogony  
Exo-erythrocytic schizogony primarily involves the replication cycle in the liver. 
Vaccinations at this point rely on the activation of host CD8+ T cells to kill infected 
hepatocytes (Draper et al., 2018). An ideal vaccine of this design would confer sterile 
protection, completely blocking erythrocytic replication. A recombinant viral vector 
vaccine derived from a chimpanzee adenovirus has shown promise in some studies, but in 
others has shown no efficacy (Draper et al., 2018). This vaccine targets a 
thrombospondin-related adhesion protein, which is involved in parasite entry into 
hepatocytes. Evidence for this vaccine is conflicted, and focus has shifted to more 
promising alternative targets (Bliss et al., 2017).  
It is difficult to isolate antigens for this method of vaccination as the exact 
expression of proteins in liver-stage P. falciparum replication is not completely known. 
Ongoing research is using structure-based vaccine design (discussed earlier) to discover 
antigens that may be utilized for a vaccine (Draper et al., 2018).  
A longstanding hypothesis is that the host immune system must be exposed twice 
to confer significant T cell activation and immunity (Fernandez-Ruiz et al., 2016). In this 
method, the host is first inoculated with the pathogen, in this case through RAS, which 
primes the T cell activation cascade. A viral vector is then administered to target the liver 
and induce the primed T cells to remain in the liver tissue. This method has been shown 
in early trial phases to induce high levels of T cells and confer protection against the 




Vaccinations against erythrocytic schizogony  
Blood stage vaccines target the P. falciparum asexual reproduction in 
erythrocytes that is responsible for the clinical presentation of malaria. Blood stage 
infection is unique in that it allows for the rise of naturally acquired immunity as a result 
of the typical activation of the host immune system. Vaccines that mimic this naturally-
acquired immunity are currently being studied in clinical trials (Draper et al., 2018). 
 Blood stage vaccines typically rely on antigens that contain full merozoites or 
subunits to block transmission between erythrocytes. Unfortunately, this method has not 
demonstrated any significant efficacy (Draper et al., 2018). A significant challenge is that 
merozoites invade erythrocytes in less than one minute, so immune cells are only exposed 
to merozoite antigens for seconds, if they even come into contact at all (Weiss et al., 
2016). This requires extremely high concentrations of antibodies to increase the 
probability of antigen-antibody binding, especially since there are so many merozoites in 
the blood stage. However, as discussed above a challenge of antimalarial design is the 
difficulty in mounting an effective host response by overcoming the highly polymorphic 
blood-stage antigens. This vaccine method requires high antibody levels, but those levels 
are difficult to achieve anyways. If sufficient antibody-antigen interaction is achieved, 
these merozoites use the same mechanism of redundant polymorphism as PfEMP1 to 
evade the host immune system (Draper et al., 2018). In fact, PfEMP1 is a common blood 
stage antimalarial vaccine target, but unfortunately it evades antibody binding through 
polymorphism too quickly to be effective (Frimpong et al., 2018). PfEMP1 vaccines are 
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currently being studied as there is growing evidence that similar pathways may be 
beneficial in preventing cerebral malaria (Jensen et al., 2020).  
PfEMP1 is one of many surface proteins on an erythrocyte. A very recent study at 
the end of 2020 published evidence for targeting the erythrocyte surface protein named P. 
falciparum glutamic acid-rich protein (PfGARP) (Raj et al., 2020). Antibodies to this 
protein were shown to induce apoptosis (programmed cell death) of trophozoites and 
were especially protective against severe malaria (Raj et al., 2020).  
The P. falciparum reticulocyte-binding protein homolog 5 (PfRH5) shows 
promise in overcoming this evasion mechanism. This protein homolog antigen is part of a 
reaction with the erythrocyte membrane that is essential to erythrocyte invasion by the 
parasite (Crosnier et al., 2011). Monkeys inoculated with this protein analog are capable 
of inhibiting further infection from all P. falciparum strains (Draper et al., 2018). 
Unfortunately, studies do not show that the vaccine protects the monkey subjects for a 
long period of time (Duffy & Patrick Gorres, 2020). Further research will measure the 
extent of growth inhibition activity and determine the level of efficacy required for future 
human trials. It is possible that future efficacy can be improved by administration with 
adjuvants and presentation of the antigen in virus-like particles (Duffy & Patrick Gorres, 
2020). Overall, this shows promise and researchers are hopeful that this vaccine method 
will overcome the challenges of immune evasion and quick entry into the erythrocyte.  
A possible target for erythrocytic schizogony vaccination is apical membrane 
antigen 1 (AMA1), which is an essential protein for development of P. falciparum in the 
blood stage (Duffy & Patrick Gorres, 2020). At the meeting of the merozoite and 
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erythrocyte, AMA1 binds to the rhoptry neck protein 2 (RON2). This is required for the 
initiation of invasion of the merozoite into the erythrocyte target. The AMA1-RON2 
complex as an antigen has shown significant protection against P. falciparum infection in 
Aotus monkeys (Srinivasan et al., 2017). This immunogenic complex shows promise for 
future clinical trials involving human participants. Similar to the PfRH5 vaccine, this 
AMA1-RON2 vaccine can be improved with further research into antigen presentation 
and possible adjuvants (Duffy & Patrick Gorres, 2020).  
 
Vaccinations against P. falciparum transmission  
Recent attention has been given to the concept of transmission-blocking vaccines 
(TBVs). TBVs are aimed at preventing the sexual replication of P. falciparum and 
limiting the transmission of the parasite between humans and the Anopheles vector 
(Draper et al., 2018). As a reminder, some ring stage trophozoites in blood turn into 
gametocytes, which are capable of sexual reproduction and are taken up by female 
mosquitoes during a blood meal. Therefore, the degree of transmission and public health 
risk is directly related to the concentration of gametocytes. Interestingly, even a low 
concentration of gametocytes is very likely to infect mosquitoes (Churcher et al., 2013). 
As transmission of these gametocytes is so easy, an ideal vaccine would be 100% 
effective and would completely eradicate the gametocytes from the blood.  
TBVs are developed with surface antigens of the gametocytes to induce an 
immune response against those parasitic cells (Duffy & Patrick Gorres, 2020). By 
inducing the immune system to kill these gametocytes, there are fewer to no gametocytes 
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left for mosquitos to pick up during a feeding, halting transmission. Interestingly, 
vaccines have been designed against surface proteins expressed by gametocytes in the 
human host (Pfs230) and against surface proteins expressed by the fertilized zygote in the 
mosquito midgut (Pfs25) (Duffy & Patrick Gorres, 2020). Pfs25 has shown the most 
promise in blocking P. falciparum transmission, so it has been the primary focus of 
transmission-blocking research (Menon et al., 2018). Variations of this vaccine have been 
produced using chimeric antigens, antigens produced using mouse and human antibodies 
(Draper et al., 2018). Clinical trials are currently underway to further examine its efficacy 
and determine if it can be made more potent through different packaging or the addition 
of adjuvants.  
TBVs are unique in that they do not directly benefit the host being inoculated. 
They do not combat the immediate infection and do not affect disease progression in the 
host (Duffy & Patrick Gorres, 2020). The vaccine recipient does not experience any relief 
of malaria symptoms. These vaccines only prevent transmission, so they confer herd 
immunity but not individual immunity. As a result, to be used widely this vaccine must 
be demonstrated to be exceptionally safe with minimal side effects. This will pose a 
challenge when encouraging individuals to receive the vaccine, especially in regions 
where malaria transmission is almost nonexistent (Figure 1). Common to other vaccines 
against this pathogen, there is significant difficulty in maintaining a high enough 
antibody concentration to effectively block gametocyte transmission. Maintaining a high 
antibody titer would likely induce more symptoms, compounding the issue of safety and 




Looking to the future 
By far the most developed and most promising P. falciparum vaccine candidate is 
the RTS,S/AS01 vaccine against the circumsporozoite protein (CSP). This vaccine has 
shown a reduction in malaria cases in African children (Duffy & Patrick Gorres, 2020). 
Phase III clinical trials for RTS,S have been completed, and it is hopeful that this vaccine 
will be approved for widespread use, especially in children (Frimpong et al., 2018). 
Current trials are underway to analyze specific cases and complications, such as use in 
severe malaria. The main improvements needed for RTS,S are improved duration of 
efficacy and a reduced number of doses. It is costly and logistically difficult to administer 
multiple doses of a vaccine, especially to large groups. Booster doses are required, and 
efficacy is still lost quickly after subsequent boosters. From preliminary findings, it is 
expected that this vaccine will proceed to the licensing stage after a thorough review by 
international (WHO) and national organizations (Draper et al., 2018).  
While vaccine research is underway, special attention is given to vulnerable 
populations that may need earlier or more robust protection. Travelers with naïve 
immune systems are encouraged to take preventative antimalarials (doxycycline) and use 
mosquito repellent sprays and bed nets (Kuna & Gajewski, 2019). Pregnant mothers that 
are infected with P. falciparum are a significant population in that the parasite can 
accumulate in the placenta. Pregnant women can naturally acquire immunity to placental 
malaria, and this immunity strengthens over successive pregnancies (Fried et al., 1998). 
Parasites found in the placenta express the unique protein VAR2CSA, a member of the 
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PfEMP1 family (Duffy & Patrick Gorres, 2020). This protein binds chondroitin sulfate A 
(CSA) to sequester itself in the placenta. Vaccines against VAR2CSA have shown 
promise, but they require a high dose, although they have proven to be safe (Mordmüller 
et al., 2019). Similar to PfSPZ administered with chloroquine, this vaccine is much less 
effective when the patient is infected with multiple strains of P. falciparum. Future 
research will focus on combinations between VAR2CSA vaccines to improve their sum 
efficacy (Duffy & Patrick Gorres, 2020).  
A very recently released study published results for a modified RTS,S vaccine 
called R21 (Ledford, 2021). This study demonstrated that this vaccine was 77% effective 
at preventing malaria after one year in African children (Datoo et al., 2021). The WHO 
requires a P. falciparum vaccine to clear the 75% effectiveness benchmark, so if 
replicable this vaccine could be the next one released for public inoculation against P. 
falciparum (Ledford, 2021). Participants in the trial also demonstrated an 86% increase in 
antibody concentration, showing promise for this common challenge of vaccine design 
(Datoo et al., 2021). Like RTS,S, the R21 antigen contains the central repeat region of the 
CSP protein, however it only has one HBsAg versus the four that RTS,S contains (Datoo 
et al., 2021). From this structure, R21 is cheaper than RTS,S and with multiple adjuvants 
it is claimed to be more potent. Clinical trials with larger sample sizes began in May of 
2021 and are ongoing (Ledford, 2021). This development is very exciting as it is the next 
closest P. falciparum vaccine being released for widespread public use, behind RTS,S.  
One of the largest challenges that vaccine research faces is mounting a sufficient 
host immune response against the antigen (King, 2019). P. falciparum is capable of 
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mutation once recognized by the host antibodies, so it is very challenging to produce the 
correct antibodies and even more so to produce them at high quantities. With the 
extremely high antigen levels at the blood stage, a large number of antibodies need to be 
produced. This problem is compounded by the fact that it takes nearly two weeks for 
antibodies to be produced, so by the time there are significant antibody titers, the parasite 
has mutated again. It is difficult to quantify these antibody levels as specific assays for T 
cell-based immunity vary greatly in their predictive abilities (Beeson et al., 2014). Also, 
antibody levels as standardized correlates of protection for viruses like influenza are not 
as predictive for P. falciparum infection. The discovery of new antigens and addition of 
adjuvants can be used to help promote a host immune response, and clinical trials using 
these methods are ongoing. Attention is also given to the dosing regimen of a vaccine, 
intending to balance a high antibody titer with as few injections as possible. Multiple 
injections, while they would confer a higher effectiveness, are logistically difficult to 
administer. Individuals offered a P. falciparum vaccine, especially in areas where 
transmission is low or nonexistent, could deny the vaccine if the administration series is 
lengthy. For transmission-based vaccines, the lack of symptomatic relief may deter 
individuals from receiving the vaccine. After overcoming these challenges and further 
investigating the many avenues of P. falciparum vaccine design, it is promising that 





DISCUSSION AND CONCLUSION 
 
 Malaria is a complex, dangerous disease that is of great public health concern. 
The parasite responsible, Plasmodium falciparum, has an incredibly complex life cycle 
and a propensity to quickly evade the host immune system once the pathogen is finally 
detected. This high degree of polymorphism is the driving force behind P. falciparum 
resistance to antimalarial drugs, like chloroquine. This mechanism of resistance is also of 
concern in vaccine development, which relies on the antigen-antibody interaction.  
 Uncomplicated malaria from P. falciparum can be cured, but if left untreated to 
develop into severe malaria, it becomes deadly. High erythrocyte lysis leads to anemia 
and infectious sporozoites cause liver failure and a cascade of dysfunction of other 
organs. The most alarming clinical aspect arises from the sequestration of infected 
erythrocytes in microvasculature, causing cerebral malaria, respiratory failure, and 
cardiac abnormalities. Patients that survive cerebral malaria are often left with lasting 
neurological dysfunction.  
 Several antimalarial drugs are approved for use, including first-line ART. 
However, P. falciparum is capable of rapidly conferring resistance to single drugs. To 
stay ahead of this parasite, the more effective public health measure is vaccination and 
eradication. The most promising vaccines candidates are the RTS,S/AS01 and the R21 
vaccines against the circumsporozoite protein. These two candidates are much closer than 
any other vaccine to approval for widespread use, although safety and efficacy trials are 
still ongoing. Early clinical trials are investigating vaccinating against the whole 
sporozoite and various surface proteins in both the liver and blood stages of parasite 
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replication. Research is ongoing for vaccines that block transmission of the pathogenic 
gametocytes, but these vaccines do not confer protection for the host being inoculated.  
Improvements to vaccine development are focusing on increasing potency to 
achieve the highest host immune response possible. With continuing research, it is 






Akkaya, M., Kwak, K., & Pierce, S. K. (2020). B cell memory: Building two walls of 
protection against pathogens. Nature Reviews. Immunology, 20(4), 229–238. 
PubMed. https://doi.org/10.1038/s41577-019-0244-2 
	
Alberts, B., Johnson, A., & Lewis, J. (2002). Helper T Cells and Lymphocyte Activation. 
In Molecular Biology of the Cell (4th ed.). Garland Science. 
https://www.ncbi.nlm.nih.gov/books/NBK26827/ 
	
Antibody Structure. (2021). https://bio.libretexts.org/@go/page/3305 
	
Aristizábal, B., & González, Á. (2013). Innate immune system. In Autoimmunity: From 
Bench to Bedside. El Rosario University Press. 
https://www.ncbi.nlm.nih.gov/books/NBK459455/ 
	
Ashley, E. A., Pyae Phyo, A., & Woodrow, C. J. (2018). Malaria. Lancet (London, 
England), 391(10130), 1608–1621. https://doi.org/10.1016/S0140-
6736(18)30324-6 
	
Beeson, J. G., Fowkes, F. J., Reiling, L., Osier, F. H., Drew, D. R., & Brown, G. V. 
(2014). Correlates of protection for Plasmodium falciparum malaria vaccine 
development: Current knowledge and future research. In Malaria Vaccine 
Development: Over 40 Years of Trials and Tribulations (pp. 80–104). Future 
Medicine Ltd. https://doi.org/10.2217/fmeb2013.13.144 
	
Bliss, C. M., Drammeh, A., Bowyer, G., Sanou, G. S., Jagne, Y. J., Ouedraogo, O., 
Edwards, N. J., Tarama, C., Ouedraogo, N., Ouedraogo, M., Njie-Jobe, J., Diarra, 
A., Afolabi, M. O., Tiono, A. B., Yaro, J. B., Adetifa, U. J., Hodgson, S. H., 
Anagnostou, N. A., Roberts, R., … Ewer, K. J. (2017). Viral Vector Malaria 
Vaccines Induce High-Level T Cell and Antibody Responses in West African 
Children and Infants. Molecular Therapy, 25(2), 547–559. 
https://doi.org/10.1016/j.ymthe.2016.11.003 
	
CDC - Malaria—About Malaria. (n.d.). Retrieved June 26, 2021, from 
https://www.cdc.gov/malaria/about/ 
	
Churcher, T. S., Bousema, T., Walker, M., Drakeley, C., Schneider, P., Ouédraogo, A. L., 
& Basáñez, M.-G. (2013). Predicting mosquito infection from Plasmodium 
falciparum gametocyte density and estimating the reservoir of infection. ELife, 2, 




Cowman, A. F., Healer, J., Marapana, D., & Marsh, K. (2016). Malaria: Biology and 
Disease. Cell, 167(3), 610–624. https://doi.org/10.1016/j.cell.2016.07.055 
	
Crosnier, C., Bustamante, L. Y., Bartholdson, S. J., Bei, A. K., Theron, M., Uchikawa, 
M., Mboup, S., Ndir, O., Kwiatkowski, D. P., Duraisingh, M. T., Rayner, J. C., & 
Wright, G. J. (2011). Basigin is a receptor essential for erythrocyte invasion by 
Plasmodium falciparum. Nature, 480(7378), 534–537. 
https://doi.org/10.1038/nature10606 
	
Datoo, M. S., Magloire Natama, H., Somé, A., Traoré, O., Rouamba, T., Bellamy, D., 
Yameogo, P., Valia, D., Tegneri, M., Ouedraogo, F., Soma, R., Sawadogo, S., 
Sorgho, F., Derra, K., Rouamba, E., Orindi, B., Ramos-Lopez, F., Flaxman, A., 
Cappuccini, F., … Tinto, H. (2021). High Efficacy of a Low Dose Candidate 
Malaria Vaccine, R21 in 1 Adjuvant Matrix-MTM, with Seasonal Administration 
to Children in Burkina Faso (SSRN Scholarly Paper ID 3830681). Social Science 
Research Network. https://doi.org/10.2139/ssrn.3830681 
	
David, P. H., Hommel, M., Miller, L. H., Udeinya, I. J., & Oligino, L. D. (1983). Parasite 
sequestration in Plasmodium falciparum malaria: Spleen and antibody modulation 
of cytoadherence of infected erythrocytes. Proceedings of the National Academy 
of Sciences of the United States of America, 80(16), 5075–5079. PubMed. 
https://doi.org/10.1073/pnas.80.16.5075 
	
Didierlaurent, A. M., Laupèze, B., Di Pasquale, A., Hergli, N., Collignon, C., & Garçon, 
N. (2017). Adjuvant system AS01: Helping to overcome the challenges of modern 
vaccines. Expert Review of Vaccines, 16(1), 55–63. 
https://doi.org/10.1080/14760584.2016.1213632 
	
Doll, K. L., & Harty, J. T. (2014). Correlates of protective immunity following whole 
sporozoite vaccination against malaria. Immunologic Research, 59(1), 166–176. 
https://doi.org/10.1007/s12026-014-8525-0 
	
Draper, S. J., Sack, B. K., King, C. R., Nielsen, C. M., Rayner, J. C., Higgins, M. K., 
Long, C. A., & Seder, R. A. (2018). Malaria Vaccines: Recent Advances and New 
Horizons. Cell Host & Microbe, 24(1), 43–56. 
https://doi.org/10.1016/j.chom.2018.06.008 
	
Duffy, P. E., & Patrick Gorres, J. (2020). Malaria vaccines since 2000: Progress, 
priorities, products. NPJ Vaccines, 5, 48–48. PubMed. 
https://doi.org/10.1038/s41541-020-0196-3 
	
Fernandez-Ruiz, D., Ng, W. Y., Holz, L. E., Ma, J. Z., Zaid, A., Wong, Y. C., Lau, L. S., 
Mollard, V., Cozijnsen, A., Collins, N., Li, J., Davey, G. M., Kato, Y., Devi, S., 
Skandari, R., Pauley, M., Manton, J. H., Godfrey, D. I., Braun, A., … Heath, W. 
	
54 
R. (2016). Liver-Resident Memory CD8+ T Cells Form a Front-Line Defense 
against Malaria Liver-Stage Infection. Immunity, 45(4), 889–902. 
https://doi.org/10.1016/j.immuni.2016.08.011 
	
Fried, M., Nosten, F., Brockman, A., Brabin, B. J., & Duffy, P. E. (1998). Maternal 
antibodies block malaria. Nature, 395(6705), 851–852. 
https://doi.org/10.1038/27570 
	
Frimpong, A., Kusi, K. A., Ofori, M. F., & Ndifon, W. (2018). Novel Strategies for 
Malaria Vaccine Design. Frontiers in Immunology, 9, 2769–2769. PubMed. 
https://doi.org/10.3389/fimmu.2018.02769 
	
Guerra Mendoza, Y., Garric, E., Leach, A., Lievens, M., Ofori-Anyinam, O., Pirçon, J.-
Y., Stegmann, J.-U., Vandoolaeghe, P., Otieno, L., Otieno, W., Owusu-Agyei, S., 
Sacarlal, J., Masoud, N. S., Sorgho, H., Tanner, M., Tinto, H., Valea, I., Mtoro, A. 
T., Njuguna, P., … Schuerman, L. (2019). Safety profile of the RTS,S/AS01 
malaria vaccine in infants and children: Additional data from a phase III 
randomized controlled trial in sub-Saharan Africa. Human Vaccines & 
Immunotherapeutics, 15(10), 2386–2398. PubMed. 
https://doi.org/10.1080/21645515.2019.1586040 
	
Hviid, L., & Jensen, A. T. R. (2015). Chapter Two—PfEMP1 – A Parasite Protein 
Family of Key Importance in Plasmodium falciparum Malaria Immunity and 
Pathogenesis. In D. Rollinson & J. R. Stothard (Eds.), Advances in Parasitology 
(Vol. 88, pp. 51–84). Academic Press. 
https://doi.org/10.1016/bs.apar.2015.02.004 
	
Idro, R., Kakooza-Mwesige, A., Asea, B., Ssebyala, K., Bangirana, P., Opoka, R. O., 
Lubowa, S. K., Semrud-Clikeman, M., John, C. C., & Nalugya, J. (2016). 
Cerebral malaria is associated with long-term mental health disorders: A cross 
sectional survey of a long-term cohort. Malaria Journal, 15(1), 184. 
https://doi.org/10.1186/s12936-016-1233-6 
	
Jennewein, M. F., & Alter, G. (2017). The Immunoregulatory Roles of Antibody 
Glycosylation. Trends in Immunology, 38(5), 358–372. 
https://doi.org/10.1016/j.it.2017.02.004 
	
Jensen, A. R., Adams, Y., & Hviid, L. (2020). Cerebral Plasmodium falciparum malaria: 
The role of PfEMP1 in its pathogenesis and immunity, and PfEMP1-based 
vaccines to prevent it. Immunological Reviews, 293(1), 230–252. PubMed. 
https://doi.org/10.1111/imr.12807 
	





Kuna, A., & Gajewski, M. (2019). Malaria vaccine for travellers—Where are we now? 
International Maritime Health, 70(1), 65–67. 
https://doi.org/10.5603/IMH.2019.0010 
	
Kurtzhals, J. A., Reimert, C. M., Tette, E., Dunyo, S. K., Koram, K. A., Akanmori, B. D., 
Nkrumah, F. K., & Hviid, L. (1998). Increased eosinophil activity in acute 
Plasmodium falciparum infection—Association with cerebral malaria. Clinical 
and Experimental Immunology, 112(2), 303–307. PubMed. 
https://doi.org/10.1046/j.1365-2249.1998.00586.x 
	
Kwiatkowski, D., Sambou, I., Twumasi, P., Greenwood, B. M., Hill, A. V. S., Manogue, 
K. R., Cerami, A., Castracane, J., & Brewster, D. R. (1990). TNF concentration in 
fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum 
malaria. The Lancet, 336(8725), 1201–1204. https://doi.org/10.1016/0140-
6736(90)92827-5 
	
Kwong, P. D. (2017). What Are the Most Powerful Immunogen Design Vaccine 
Strategies? A Structural Biologist’s Perspective. Cold Spring Harbor Perspectives 
in Biology, 9(11), a029470. PubMed. https://doi.org/10.1101/cshperspect.a029470 
	
Laurens, M. B. (2020). RTS,S/AS01 vaccine (MosquirixTM): An overview. Human 
Vaccines & Immunotherapeutics, 16(3), 480–489. PubMed. 
https://doi.org/10.1080/21645515.2019.1669415 
	
Ledford, H. (2021). Malaria vaccine shows promise—Now come tougher trials. Nature, 
593(7857), 17–17. https://doi.org/10.1038/d41586-021-01096-7 
	
Luzolo, A. L., & Ngoyi, D. M. (2019). Cerebral malaria. Brain Disorders Endemic to 
Africa, 145, 53–58. https://doi.org/10.1016/j.brainresbull.2019.01.010 
	
Madhav, H., & Hoda, N. (2021). An insight into the recent development of the clinical 
candidates for the treatment of malaria and their target proteins. European 
Journal of Medicinal Chemistry, 210, 112955. 
https://doi.org/10.1016/j.ejmech.2020.112955 
	
Maekawa, E., Aonuma, H., Nelson, B., Yoshimura, A., Tokunaga, F., Fukumoto, S., & 
Kanuka, H. (2011). The role of proboscis of the malaria vector mosquito 
Anopheles stephensi in host-seeking behavior. Parasites & Vectors, 4(1), 10. 
https://doi.org/10.1186/1756-3305-4-10 
	
Maier, A. G., Matuschewski, K., Zhang, M., & Rug, M. (2019). Plasmodium falciparum. 




Malaria. (n.d.). World Health Organization. Retrieved June 26, 2021, from 
https://www.who.int/news-room/fact-sheets/detail/malaria 
	
Mbengue, A., Bhattacharjee, S., Pandharkar, T., Liu, H., Estiu, G., Stahelin, R. V., Rizk, 
S. S., Njimoh, D. L., Ryan, Y., Chotivanich, K., Nguon, C., Ghorbal, M., Lopez-
Rubio, J.-J., Pfrender, M., Emrich, S., Mohandas, N., Dondorp, A. M., Wiest, O., 
& Haldar, K. (2015). A molecular mechanism of artemisinin resistance in 
Plasmodium falciparum malaria. Nature, 520(7549), 683–687. 
https://doi.org/10.1038/nature14412 
	
McCall, M. B. B., Yap, X. Z., & Bousema, T. (2020). Optimizing RTS,S Vaccination 
Strategies: Give It Your Best Parting Shot. The Journal of Infectious Diseases, 
222(10), 1581–1584. https://doi.org/10.1093/infdis/jiaa423 
	
Megías, M., Molist, P., & Pombal, M. (2019). Animal tissues. Atlas of Plant and Animal 
Histology. http://mmegias.webs.uvigo.es/index.html 
	
Menon, V., Kapulu, M. C., Taylor, I., Jewell, K., Li, Y., Hill, F., Long, C. A., Miura, K., 
& Biswas, S. (2018). Assessment of Antibodies Induced by Multivalent 
Transmission-Blocking Malaria Vaccines. Frontiers in Immunology, 8. 
https://doi.org/10.3389/fimmu.2017.01998 
	
Milner, D. A. (2018). Malaria Pathogenesis. Cold Spring Harbor Perspectives in 
Medicine, 8(1). https://doi.org/10.1101/cshperspect.a025569 
	
Mok, S., Ashley, E. A., Ferreira, P. E., Zhu, L., Lin, Z., Yeo, T., Chotivanich, K., 
Imwong, M., Pukrittayakamee, S., Dhorda, M., Nguon, C., Lim, P., Amaratunga, 
C., Suon, S., Hien, T. T., Htut, Y., Faiz, M. A., Onyamboko, M. A., Mayxay, M., 
… Bozdech, Z. (2015). Drug resistance. Population transcriptomics of human 
malaria parasites reveals the mechanism of artemisinin resistance. Science (New 
York, N.Y.), 347(6220), 431–435. https://doi.org/10.1126/science.1260403 
	
Moon, J. E., Ockenhouse, C., Regules, J. A., Vekemans, J., Lee, C., Chuang, I., Traskine, 
M., Jongert, E., Ivinson, K., Morelle, D., Komisar, J. L., Lievens, M., Sedegah, 
M., Garver, L. S., Sikaffy, A. K., Waters, N. C., Ballou, W. R., Ofori-Anyinam, 
O., & RTS,S Malaria Vaccine Working Group. (2020). A Phase IIa Controlled 
Human Malaria Infection and Immunogenicity Study of RTS,S/AS01E and 
RTS,S/AS01B Delayed Fractional Dose Regimens in Malaria-Naive Adults. The 
Journal of Infectious Diseases, 222(10), 1681–1691. 
https://doi.org/10.1093/infdis/jiaa421 
	
Mordmüller, B., Sulyok, M., Egger-Adam, D., Resende, M., de Jongh, W. A., Jensen, M. 
H., Smedegaard, H. H., Ditlev, S. B., Soegaard, M., Poulsen, L., Dyring, C., 
Calle, C. L., Knoblich, A., Ibáñez, J., Esen, M., Deloron, P., Ndam, N., Issifou, S., 
	
57 
Houard, S., … Nielsen, M. A. (2019). First-in-human, Randomized, Double-blind 
Clinical Trial of Differentially Adjuvanted PAMVAC, A Vaccine Candidate to 
Prevent Pregnancy-associated Malaria. Clinical Infectious Diseases : An Official 
Publication of the Infectious Diseases Society of America, 69(9), 1509–1516. 
PubMed. https://doi.org/10.1093/cid/ciy1140 
	
Moser, K. A., Drábek, E. F., Dwivedi, A., Stucke, E. M., Crabtree, J., Dara, A., Shah, Z., 
Adams, M., Li, T., Rodrigues, P. T., Koren, S., Phillippy, A. M., Munro, J. B., 
Ouattara, A., Sparklin, B. C., Dunning Hotopp, J. C., Lyke, K. E., Sadzewicz, L., 
Tallon, L. J., … Silva, J. C. (2020). Strains used in whole organism Plasmodium 
falciparum vaccine trials differ in genome structure, sequence, and immunogenic 
potential. Genome Medicine, 12(1), 6–6. PubMed. 
https://doi.org/10.1186/s13073-019-0708-9 
	
National Center for Chronic Disease Prevention and Health Promotion (US) Office on 
Smoking and Health. (2014). The Health Consequences of Smoking—50 Years of 
Progress: A Report of the Surgeon General. 
https://www.ncbi.nlm.nih.gov/books/NBK294318/figure/ch10.f5/ 
	
Oyen, D., Torres, J. L., Wille-Reece, U., Ockenhouse, C. F., Emerling, D., Glanville, J., 
Volkmuth, W., Flores-Garcia, Y., Zavala, F., Ward, A. B., King, C. R., & Wilson, 
I. A. (2017). Structural basis for antibody recognition of the NANP repeats in 
Plasmodium falciparum circumsporozoite protein. Proceedings of the National 
Academy of Sciences of the United States of America, 114(48), E10438–E10445. 
PubMed. https://doi.org/10.1073/pnas.1715812114 
	
Palacpac, N. M. Q., & Horii, T. (2020). Malaria vaccines: Facing unknowns. 
F1000Research, 9, F1000 Faculty Rev-296. PubMed. 
https://doi.org/10.12688/f1000research.22143.1 
	
Pollard, A. J., & Bijker, E. M. (2021). A guide to vaccinology: From basic principles to 
new developments. Nature Reviews Immunology, 21(2), 83–100. 
https://doi.org/10.1038/s41577-020-00479-7 
	
Raj, D. K., Das Mohapatra, A., Jnawali, A., Zuromski, J., Jha, A., Cham-Kpu, G., 
Sherman, B., Rudlaff, R. M., Nixon, C. E., Hilton, N., Oleinikov, A. V., 
Chesnokov, O., Merritt, J., Pond-Tor, S., Burns, L., Jolly, G., Ben Mamoun, C., 
Kabyemela, E., Muehlenbachs, A., … Kurtis, J. D. (2020). Anti-PfGARP 
activates programmed cell death of parasites and reduces severe malaria. Nature, 
582(7810), 104–108. PubMed. https://doi.org/10.1038/s41586-020-2220-1 
	
Roestenberg, M., Teirlinck, A. C., McCall, M. B., Teelen, K., Makamdop, K. N., 
Wiersma, J., Arens, T., Beckers, P., van Gemert, G., van de Vegte-Bolmer, M., 
van der Ven, A. J., Luty, A. J., Hermsen, C. C., & Sauerwein, R. W. (2011). 
	
58 
Long-term protection against malaria after experimental sporozoite inoculation: 
An open-label follow-up study. The Lancet, 377(9779), 1770–1776. 
https://doi.org/10.1016/S0140-6736(11)60360-7 
	
RTS, S. C. T. P. (2015). Efficacy and safety of RTS,S/AS01 malaria vaccine with or 
without a booster dose in infants and children in Africa: Final results of a phase 3, 
individually randomised, controlled trial. Lancet (London, England), 386(9988), 
31–45. PubMed. https://doi.org/10.1016/S0140-6736(15)60721-8 
	
Sissoko, M. S., Healy, S. A., Katile, A., Omaswa, F., Zaidi, I., Gabriel, E. E., Kamate, B., 
Samake, Y., Guindo, M. A., Dolo, A., Niangaly, A., Niaré, K., Zeguime, A., 
Sissoko, K., Diallo, H., Thera, I., Ding, K., Fay, M. P., O’Connell, E. M., … 
Duffy, P. E. (2017). Safety and efficacy of PfSPZ Vaccine against Plasmodium 
falciparum via direct venous inoculation in healthy malaria-exposed adults in 
Mali: A randomised, double-blind phase 1 trial. The Lancet. Infectious Diseases, 
17(5), 498–509. PubMed. https://doi.org/10.1016/S1473-3099(17)30104-4 
	
Srinivasan, P., Baldeviano, G. C., Miura, K., Diouf, A., Ventocilla, J. A., Leiva, K. P., 
Lugo-Roman, L., Lucas, C., Orr-Gonzalez, S., Zhu, D., Villasante, E., Soisson, 
L., Narum, D. L., Pierce, S. K., Long, C. A., Diggs, C., Duffy, P. E., Lescano, A. 
G., & Miller, L. H. (2017). A malaria vaccine protects Aotus monkeys against 
virulent Plasmodium falciparum infection. NPJ Vaccines, 2, 14. 
https://doi.org/10.1038/s41541-017-0015-7 
	
Taylor, T. E., & Molyneux, M. E. (2015). The pathogenesis of pediatric cerebral malaria: 
Eye exams, autopsies, and neuroimaging. Annals of the New York Academy of 
Sciences, 1342(1), 44–52. PubMed. https://doi.org/10.1111/nyas.12690 
	
Taylor, W. R. J., Hanson, J., Turner, G. D. H., White, N. J., & Dondorp, A. M. (2012). 
Respiratory manifestations of malaria. Chest, 142(2), 492–505. 
https://doi.org/10.1378/chest.11-2655 
	
Thien, H. V., Kager, P. A., & Sauerwein, H. P. (2006). Hypoglycemia in falciparum 
malaria: Is fasting an unrecognized and insufficiently emphasized risk factor? 
Trends in Parasitology, 22(9), 410–415. https://doi.org/10.1016/j.pt.2006.06.014 
	
Tijani, M. K., Reddy, S. B., Langer, C., Beeson, J. G., Wahlgren, M., Nwuba, R. I., & 
Persson, K. E. M. (2018). Factors influencing the induction of high affinity 
antibodies to Plasmodium falciparum merozoite antigens and how affinity 





Vandoolaeghe, P., & Schuerman, L. (2016). The RTS,S/AS01 malaria vaccine in children 
5 to 17 months of age at first vaccination. Expert Review of Vaccines, 15(12), 
1481–1493. https://doi.org/10.1080/14760584.2016.1236689 
	
Vetter, V., Denizer, G., Friedland, L. R., Krishnan, J., & Shapiro, M. (2018). 
Understanding modern-day vaccines: What you need to know. Annals of 
Medicine, 50(2), 110–120. https://doi.org/10.1080/07853890.2017.1407035 
	
von Seidlein, L., Hanboonkunupakarn, B., Jittamala, P., Pongsuwan, P., Chotivanich, K., 
Tarning, J., Hoglund, R. M., Winterberg, M., Mukaka, M., Peerawaranun, P., 
Sirithiranont, P., Doran, Z., Ockenhouse, C. F., Ivinson, K., Lee, C., Birkett, A. J., 
Kaslow, D. C., Singhasivanon, P., Day, N. P. J., … Pukrittayakamee, S. (2020). 
Combining antimalarial drugs and vaccine for malaria elimination campaigns: A 
randomized safety and immunogenicity trial of RTS,S/AS01 administered with 
dihydroartemisinin, piperaquine, and primaquine in healthy Thai adult volunteers. 
Human Vaccines & Immunotherapeutics, 16(1), 33–41. 
https://doi.org/10.1080/21645515.2019.1643675 
	
Walk, J., Reuling, I. J., Behet, M. C., Meerstein-Kessel, L., Graumans, W., van Gemert, 
G.-J., Siebelink-Stoter, R., van de Vegte-Bolmer, M., Janssen, T., Teelen, K., de 
Wilt, J. H. W., de Mast, Q., van der Ven, A. J., Diez Benavente, E., Campino, S., 
Clark, T. G., Huynen, M. A., Hermsen, C. C., Bijker, E. M., … Sauerwein, R. W. 
(2017). Modest heterologous protection after Plasmodium falciparum sporozoite 
immunization: A double-blind randomized controlled clinical trial. BMC 
Medicine, 15(1), 168–168. PubMed. https://doi.org/10.1186/s12916-017-0923-4 
	
Wassmer, S. C., Taylor, T. E., Rathod, P. K., Mishra, S. K., Mohanty, S., Arevalo-
Herrera, M., Duraisingh, M. T., & Smith, J. D. (2015). Investigating the 
Pathogenesis of Severe Malaria: A Multidisciplinary and Cross-Geographical 
Approach. The American Journal of Tropical Medicine and Hygiene, 93(3 Suppl), 
42–56. PubMed. https://doi.org/10.4269/ajtmh.14-0841 
	
Weiss, G. E., Crabb, B. S., & Gilson, P. R. (2016). Overlaying Molecular and Temporal 
Aspects of Malaria Parasite Invasion. Trends in Parasitology, 32(4), 284–295. 
https://doi.org/10.1016/j.pt.2015.12.007 
	
Wellems, T. E., & Plowe, C. V. (2001). Chloroquine-Resistant Malaria. The Journal of 
Infectious Diseases, 184(6), 770–776. https://doi.org/10.1086/322858 
  
	
60 
CURRICULUM VITAE 
	
61 
 
